Akt-Khib

ACT-HIB: Vaccine against Haemophilus influenzae

ACT-HIB is a vaccine that is intended to prevent Haemophilus influenzae infection caused by the bacteria Haemophilus influenzae type b. This infection can lead to various serious diseases such as meningitis, sepsis, pneumonia and others.

ACT-HIB is produced by Aventis Pasteur and Pasteur Merrier Connaught, located in France. This vaccine belongs to the pharmaceutical group of vaccines and has the international name ACT-HIB.

ACT-HIB is presented in two dosage forms: lyophilized powder for the preparation of an injection solution and lyophilisate for the preparation of a solution for intramuscular and subcutaneous administration. Both forms are a single dose of vaccine.

ACT-HIB contains selected components of the bacterium Haemophilus influenzae type b, which stimulate the body's immune system to protect it from infection. The vaccine is recommended for vaccinations in children aged 2 months to 5 years, as well as for adult patients with an increased risk of disease.

ACT-HIB was one of the first vaccines developed to prevent Haemophilus influenzae infection. Since its release in 1987, it has been widely used throughout the world and has proven to be effective and safe.

Overall, ACT-HIB is an important vaccine that helps prevent Haemophilus influenzae infection and protect public health. If you would like more information about this vaccine, ask your doctor or pharmacist.